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stant for the solute, and Kc and Kd hindrance fac-
tors for convection and diffusion, respectively.
Measurements on isolated glomerular base-
ment membranes2 suggest that ΦKc = 0.2 and 
ΦKd = 0.02. The latter value shows that diffusion 
is markedly impaired in the glomerular basement 
membrane as compared with diffusion in water 
(2% of D), but convective transport is also re-
stricted. The key point is whether diffusion is 
more limited than convection; the Pe reflects this. 
A Pe above unity indicates that transport occurs 
mainly by convection, and a Pe of less than 1 re-
flects diffusion-dominated transport.
The Pe in glomerular basement membrane for 
VEGF can be estimated by using a value of v close 
to 4×10−4 cm per second and δ close to 2×10−5 cm. 
VEGF has a Stokes–Einstein radius (rs ) of 
2.6 nm, which implies that D2.6 nm is 1.26×10−6 cm2 
per second. Inserting these values into equation 1 
results in a Pe of 0.063. It is safe to conclude that 
VEGF is transported by diffusion, and diffusion 
alone, across the glomerular basement mem-
brane.
The model presented by Katavetin and Katave-
tin has the virtue of simplicity but would appear 
to be an oversimplification. For example, one 
needs to incorporate the effects of serial barriers1 
to allow for better predictions of concentrations 
at the endothelium.
Also, as stated by Katavetin and Katavetin, the 
general perception is that transport across the 
glomerular barrier is completely dominated by 
convection. In fact, the opposite is true.2 Thus, the 
flow conditions in the glomerular basement mem-
brane  resemble not a waterfall but, rather, a great 
lake with slow flow velocity. Consequently, dif-
fusion dominates the transport of most solutes in 
the glomerular basement membrane.2
We thank Nochy et al. for pointing out an ad-
ditional published case report by Frangié et al.3 
The issue of reversibility of thrombotic microan-
giopathy raised by the authors is important.4 Al-
though renal function improved in the six cases 
we reported, we were unable to determine wheth-
er it returned to baseline. Frangié et al. found 
that although hypertension and hemolysis im-
proved, the proteinuria persisted between cycles; 
this may reflect podocyte loss and segmental 
sclerosis, as shown in their report. We are aware 
of a patient at the University of Toronto in whom 
irreversible chronic kidney injury apparently de-
veloped and progressed to end-stage renal failure, 
despite discontinuation of the VEGF inhibitor.
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Case 11-2008: Mental-Status Changes  
after Liver Transplantation
To the Editor: We would like to make two 
points about the case of disseminated cryptococ-
cosis in a liver-transplant recipient, discussed in 
the Case Records by Fishman et al. (April 10 issue).1 
The first point concerns delayed diagnosis of this 
infection in patients with negative tests for hu-
man immunodeficiency virus infection. We be-
lieve that in the case presented, a correct diagno-
sis could have been suspected from day 13 onward 
on the basis of the patient’s recurrent headaches. 
In immunocompromised patients, severe and per-
sistent headache should prompt the performance 
of lumbar puncture.2
The second point is the low awareness among 
physicians of the diagnostic utility of cryptococ-
cal antigen determination in serum.3 As shown 
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in Table 1, of 153 organ-transplant recipients with 
cryptococcal meningitis in two reports, only 43 
(28%) underwent serum cryptococcal antigen 
testing.4,5 This is surprising, since in transplant 
recipients and patients with AIDS, determination 
of serum cryptococcal antigen is highly sensitive 
and only slightly less specific than cryptococcal 
antigen determination in the cerebrospinal fluid. 
We thus advocate assessment of serum cryptococ-
cal antigen in all immunocompromised patients 
with fever or headache lasting more than 3 days, 
whether or not meningeal signs are present.
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To the Editor: The case presentation notes that 
serologic testing showed the presence of anti-
bodies against hepatitis B core and surface anti-
gens; the test for hepatitis B surface antigen was 
negative. These results argue against the patient’s 
having chronic hepatitis B disease. Fishman, in 
his discussion, states that the patient had end-stage 
liver disease due to hepatitis C and hepatitis B 
infections and alcoholism. With the positive tests 
for hepatitis B antibodies and the negative test 
for surface antigen, it is not likely that hepatitis B 
contributed to the patient’s liver disease. Fishman 
also states that reactivation of hepatitis B might 
occur in the course of treatment after transplan-
tation. Although this is not impossible, the like-
lihood that hepatitis B would become reactivated 
seems remote, even in an immunosuppressed per-
son, with the serologic findings noted in the pa-
tient under discussion. Furthermore, it also seems 
very unlikely that the patient would have been at 
risk for invasive fungal disease as a result of his 
prior hepatitis B infection.
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The discussants reply: Clinical suspicion is the 
key element in establishing a diagnosis of cryp-
tococcal meningitis or for any infection of the 
central nervous system in immunocompromised 
hosts. All such patients with suspected central 
nervous system infection or persistent headache 
should undergo imaging of the central nervous 
system and, if appropriate, lumbar puncture with 
suitable diagnostic evaluations.1 As Antinori and 
Corbellino note, the serum or cerebrospinal fluid 
cryptococcal antigen assay is a useful assay for 
the diagnosis of infection in both immunocom-
promised hosts with AIDS and immunocompro-
mised hosts without AIDS. If the suspicion of cryp-
tococcal infection is high, a positive assay should 
suggest that the choice for initial therapy is an 
amphotericin product and that echinocandin ther-
apy is likely to be ineffective. In addition, early 
attention to the possibility of increased intracra-
nial pressures and combination therapy (with flu-
cytosine) should be considered. In contrast, cryp-
tococcal antigen is less useful in management. As 
in this patient, persistent elevation of cryptococ-
Table 1. Diagnostic Value of Various Tests for Cryptococcal Meningitis in Recipients of Solid-Organ Transplants.*
Study
No. of  
Patients
Serum Cryptococcal  
Antigen CSF Antigen CSF Culture India Ink 
no. with positive result/total no.(%)
Husain et al.4 125 18/21 (86) 37/37 (100) 76/82 (93) 36/47 (77)
Wu et al.5 28 20/22 (91) 28/28 (100) 21/28 (75) 14/28 (50)
Total 153 38/43 (88) 65/65 (100) 97/110 (88) 50/75 (67)
* CSF denotes cerebrospinal fluid.
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cal antigen may occur even in patients without 
demonstrably viable organisms. The development 
of highly sensitive, specific, and quantitative diag-
nostic tools for fungal infections would improve 
the management of such life-threatening episodes.
In immunocompromised patients with fungal 
infections, various factors that may have contrib-
uted to the risk for infection need to be considered 
and, if possible, ameliorated. These factors include 
recent intensification of immunosuppression, con-
comitant viral infections, and unusual epidemio-
logic exposures. Thus, active infections (e.g., with 
cytomegalovirus) are treated to enhance the re-
sponse to antifungal therapy. The ability to reduce 
the intensity of immunosuppression must be con-
sidered on an individual basis and carries some 
risk of graft rejection. Most recipients of solid-
organ transplants have multiple risk factors; the 
contribution of individual factors is less certain. 
In patients with viral hepatitis, the relative con-
tributions of active viral infection, cirrhosis, and 
the treatment of these infections are unclear. Thus, 
as Joy indicates, in the case under consideration, 
the contribution of hepatitis B is most likely to 
be through cirrhosis and for the risk of estab-
lishment of fungal colonization in the pretrans-
plantation period and the potential risk of viral 
reactivation in the context of immunosuppression 
after transplantation. As the shortage of donor 
organs persists, the use of livers that are positive 
for core antigen, and thus for hepatitis B DNA, 
is likely to increase. The full effect of the use of 
donor organs according to expanded criteria has 
yet to be ascertained.
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Shifts in Health Information
To the Editor: In their Sounding Board article 
on shifts in health information, Mandl and Ko-
hane (April 17 issue)1 observe that “companies 
providing PCHRs [personally controlled health 
records] are not covered entities under the Health 
Insurance Portability and Accountability Act 
(HIPAA),” but incorrectly suggest that extending 
HIPAA to them would improve privacy. Publicly 
available PCHR systems are already prohibited 
from releasing information to private parties 
without the consent of the account holder under 
the federal Electronic Communications Privacy 
Act.2 However, HIPAA’s privacy rule provision for 
disclosure without consent for “treatment, pay-
ment, or healthcare operations” (TPO) actually 
eliminates privacy. Although it at first appears to 
be quite reasonable, the decision about whether a 
specific disclosure is for TPO is made solely by 
the entity that holds the information, with no 
notice to the patient, no possibility for review or 
appeal, and no required audit trail. Clearly, the 
information holder is conflicted in making this 
decision and would tend to classify all desired 
disclosures as TPO. Further, the lack of audit-trail 
requirements for TPO disclosures means that there 
is no way to detect or assess abuse or violations. 
Therefore, extending HIPAA coverage would al-
low the use of PCHR information without consent, 
nullifying consumer control and privacy.
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To the Editor: Mandl and Kohane have tilted 
toward a more optimistic scenario for PCHRs than 
is currently warranted. Although they mention 
several potential problems, they have failed to 
mention one of the most serious issues: the po-
tential undermining of the value, accuracy, and 
completeness of provider records. In this brave 
new world, every provider will still have the obli-
gation to keep a clinical, legal, and business rec-
ord of all patient encounters, and indeed, physi-
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